focus -WSS

focus

author：leisure time 2025-09-29 03:13:46 Page View：6

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Insurer loopholes limit power of law against surprise medical bills
Next article： Anesthesiologist group: stop taking Ozempic before surgery

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Readout Newsletter: New research from Sanofi, Regeneron, etc.

HyacinthEmpinado/STATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiote

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Covid silver lining: Unprecedented look at human immune system

MollyFergusonforSTATWhileanincreasinglyanxiousworldwatchedanewcoronavirusspreadacrosstheglobeinearly